Načítá se...
The First Frontier: Digital Biomarkers for Neurodegenerative Disorders
Current measures of neurodegenerative diseases are highly subjective and based on episodic visits. Consequently, drug development decisions rely on sparse, subjective data, which have led to the conduct of large-scale phase 3 trials of drugs that are likely not effective. Such failures are costly, d...
Uloženo v:
| Vydáno v: | Digit Biomark |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger AG
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7015357/ https://ncbi.nlm.nih.gov/pubmed/32095743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000477383 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|